Zacks.com on MSN5d
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks Research Has Positive Forecast for CRSP Q2 Earnings
Equities researchers at Zacks Research upped their Q2 2025 earnings estimates for CRISPR Therapeutics in a report issued on ...
Shareholders in CRISPR Therapeutics (NASDAQ:CRSP) are in the red if they invested a year ago
Investors in CRISPR Therapeutics AG (NASDAQ:CRSP) have tasted that bitter downside in the last year, as the share price dropped 46%. That contrasts poorly with the market return of 15%. At least the ...
CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)
CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...
Analysts Set Expectations for CRSP FY2027 Earnings
Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for CRISPR Therapeutics in a report ...
Investing3d
Crispr Therapeutics AG (CRSP)
On Wednesday, CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of ...
Morningstar2d
CRISPR Therapeutics AG CRSP
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...